Rosalind Advisors Inc. Has $7.15 Million Stock Holdings in Cybin Inc. (NYSE:CYBN)

Rosalind Advisors Inc. lowered its position in shares of Cybin Inc. (NYSE:CYBN) by 24.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 810,918 shares of the company’s stock after selling 264,187 shares during the quarter. Cybin accounts for about 3.6% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 11th biggest holding. Rosalind Advisors Inc.’s holdings in Cybin were worth $7,152,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of CYBN. Global Retirement Partners LLC bought a new position in shares of Cybin during the fourth quarter worth about $46,000. Cowa LLC acquired a new stake in shares of Cybin during the 4th quarter worth about $115,000. Essential Planning LLC. acquired a new stake in Cybin during the 4th quarter worth approximately $138,000. Finally, Fore Capital LLC grew its stake in shares of Cybin by 70.6% in the fourth quarter. Fore Capital LLC now owns 31,421 shares of the company’s stock valued at $277,000 after acquiring an additional 13,000 shares in the last quarter. Institutional investors own 17.94% of the company’s stock.

Cybin Price Performance

NYSE CYBN opened at $7.31 on Friday. Cybin Inc. has a 12 month low of $6.50 and a 12 month high of $17.86. The company has a fifty day moving average of $8.76. The stock has a market cap of $157.00 million, a price-to-earnings ratio of -1.67 and a beta of 0.50.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. HC Wainwright reduced their price objective on shares of Cybin from $190.00 to $150.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Canaccord Genuity Group lowered their price objective on Cybin from $86.00 to $73.00 and set a “buy” rating for the company in a research report on Wednesday, February 12th. Finally, Guggenheim began coverage on Cybin in a research note on Thursday, March 13th. They issued a “buy” rating and a $35.00 price target on the stock.

Cybin Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.